Company intelligence / Profile preview

D3

Wuxi, Jiangsu, Chinad3js.org ↗

Ownership: Private
Development stage: Other

Overview

D3 Bio’s lead program is a next-generation small molecule targeting KRAS G12C mutations in multiple cancers. Early data suggest potential best-in-class properties. The pipeline includes an ERK inhibitor and a novel bispecific antibody targeting HER2 and CD47. Combination approaches are being explored preclinically.

Therapeutic areas: Oncology
Modalities: Small moleculeBispecific monoclonal antibodyMonoclonal antibody fragmentBiologic
Industry: Biotech

Beyond the preview

Go deeper on D3.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D3.

Explore the full profile